Safety and Immunogenicity of VEE Vaccine TC-83 in At-Risk Adults

Phase 2, open-label, single-arm trial of Venezuelan equine encephalitis vaccine TC-83 in Venezuelan equine encephalomyelitis (VEE), sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: Occurrence of Serious Adverse Events and Adverse Events at 15 months, Percentage of subjects with symptoms following VEE vaccination at 15 months and 1 more. Status: unknown.